Cystic Fibrosis Foundation issued the following clinical trial alerts in May.
May 3, 2021
MAYFLOWERS: Study of pregnancy in women with cystic fibrosis
Status: Enrolling
Description: This observational study will evaluate the effects of CFTR modulators on women with CF during and after pregnancy. CFTR modulators are intended to help CFTR protein function closer to normal.
Age: 16 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 9
Length of Participation: 35 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04828382
Study to evaluate ARO-ENaC in adults with cystic fibrosis
Status: Enrolling
Description: This study will evaluate the safety and tolerability of ARO-ENaC, a drug intended to thin airway surface liquid. Multiple doses of the drug will be tested in adults with cystic fibrosis to find the optimal dose.
Age: 18 Years to 55 Years
Mutation: No Mutation Requirement
Fev1% Predicted: 40 to 99%
Number of Visits: 12
Length of Participation: 113 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04375514